Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2009
Business Overview: NAI is a formulator, manufacturer, and marketer of nutritional supplements. Its primary business is private label contract manufacturing for vitamins, minerals, and herbs. The company also markets its own branded products under the "Pathway to Healing" line. During the fiscal year, NAI completed the sale of substantially all assets of its legacy Real Health Laboratories (RHL) business, which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Net Sales (Continuing Ops) | $73.9 million | $81.8 million |
| Gross Profit | $9.4 million (13% margin) | $12.9 million (16% margin) |
| Operating Income (Continuing Ops) | $0.4 million | $1.1 million |
| Net Loss (Continuing Ops) | $(0.2) million | $0.9 million (Income) |
| Loss from Discontinued Ops | $(3.9) million | $(1.3) million |
| Total Net Loss | $(4.1) million | $(0.4) million |
| Cash from Operating Activities | $4.9 million | $2.7 million |
| Total Debt | $1.3 million | $2.7 million |
| Cash and Equivalents | $4.0 million | $3.5 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales from continuing operations decreased 10% to $73.9 million. Private label contract manufacturing sales fell 8.5% due to lower volumes from top customers and unfavorable foreign currency fluctuations. Branded product sales dropped 31.4% following the cessation of Dr. Cherry's television program.
- Margin Compression: Gross profit margin declined 3.1 percentage points to 13%, driven by a shift to lower-margin products, higher per-unit manufacturing costs due to lower production levels, and increased testing costs for GMP compliance.
- Discontinued Operations: The company recorded a $3.9 million loss from discontinued operations, primarily due to a $1.8 million impairment charge on RHL assets and $1.0 million in restructuring costs associated with the sale of the RHL business.
- Cost Reduction: A cost reduction program implemented in Q2 2009 resulted in a $0.6 million charge but generated $3.0 million in savings in the second half of the year compared to the prior year.
Guidance, Outlook, and Risks
- Outlook: Management anticipates generating positive net income in the first quarter of fiscal 2010. The cost reduction program is expected to reduce operating overhead by approximately $3.5 million in fiscal 2010 compared to fiscal 2009.
- Strategy: Focus remains on leveraging certified facilities for private label customers, growing the "Pathway to Healing" branded line through direct-to-consumer marketing, and commercializing the licensed patent estate (Beta-Alanine).
- Liquidity: The company has $4.0 million in cash and $5.2 million available under its line of credit. Management believes this is sufficient to fund operations for the next 12 months.
- Key Risks:
- Customer Concentration: Two customers (NSA International and Mannatech) accounted for 79% of continuing operations sales in 2009.
- Covenant Compliance: The company failed to meet certain loan covenants during fiscal 2009 but obtained waivers. Future compliance is required to maintain access to credit.
- Goodwill Impairment: Risk of future impairment charges on goodwill and intangible assets remains due to economic conditions.
Investor Verification Checklist
- Verify the stability of the two largest customers (NSA International and Mannatech), which represent nearly 80% of revenue.
- Confirm the status of loan covenants and the lender's continued willingness to waive defaults if financial metrics fluctuate.
- Assess the effectiveness of the new marketing initiatives for the "Pathway to Healing" line in offsetting the loss of the television program.
- Monitor the realization of the $3.5 million projected cost savings in fiscal 2010.
- Review the valuation of the $1.8 million deferred tax asset valuation allowance and the likelihood of future reversals.